Current Research Studies

Cancer - ACNS1422: Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Condition or Therapy:

WNT-driven medulloblastoma


Cancer and Blood Disorders

What is the goal of this study?

The goal of this study is to to estimate the progression free survival rate of patients with WNT medulloblastoma using reduced craniospinal radiotherapy and reduced chemotherapy approach.

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are 3 to 21 years old
  • Are newly diagnosed with classical histologic type (non LC/A) WNT medulloblastoma, positive nuclear B-catenin by IHC, positive for CTNNB1 mutation, and negative for MYC and MYCN by FISH.

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or send us an email.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Douglas Hawkins